RYTM
Rhythm Pharmaceuticals Inc.
$99.00
+$2.94(+3.06%)
81
Overall
--
Value
81
Tech
--
Quality
Market Cap
$6.38B
Volume
771.63K
52W Range
$45.91 - $106.52
Target Price
$111.93
Order:
Income Statement
| Metric | Trend | Chart | 2017 Dec | 2018 Dec | 2019 Dec | 2020 Dec | 2021 Dec | 2022 Dec | 2023 Dec | 2024 Dec |
|---|---|---|---|---|---|---|---|---|---|---|
| REVENUE | ||||||||||
| Total Revenue | -- | -- | -- | -- | $3.2M | $23.6M | $77.4M | $130.1M | ||
| Total Revenue | -- | -- | -- | -- | $3.2M | $23.6M | $77.4M | $130.1M | ||
| COST OF GOODS SOLD | ||||||||||
| Cost of Revenue | $-180.0K | -- | -- | -- | $599.0K | $2.1M | $9.3M | $13.4M | ||
| GROSS PROFIT | ||||||||||
| Gross Profit | $180.0K | -- | -- | -- | $2.6M | $21.5M | $68.1M | $116.8M | ||
| OPERATING EXPENSES | ||||||||||
| Operating Expenses | $-32.4M | $-78.4M | $146.0M | $136.6M | $172.6M | $200.7M | $252.5M | $382.3M | ||
| Research & Development | $22.9M | $50.3M | $109.5M | $90.5M | $104.1M | $108.6M | $135.0M | $238.0M | ||
| Research Expense | $22.9M | $50.3M | $109.5M | $90.5M | $104.1M | $108.6M | $135.0M | $238.0M | ||
| Selling, General & Administrative | $9.5M | $28.1M | $36.5M | $46.1M | $68.5M | $92.0M | $117.5M | $144.3M | ||
| Selling & Marketing Expenses | $9.5M | $28.1M | -- | -- | -- | -- | -- | -- | ||
| General & Administrative Expenses | $-215.0K | $-359.0K | $36.5M | $46.1M | $68.5M | $92.0M | $117.5M | $144.3M | ||
| Salaries & Wages | -- | -- | -- | -- | -- | $19.8M | $32.6M | $39.7M | ||
| Depreciation & Amortization | -- | $-442.0K | $834.0K | $690.0K | $816.0K | $896.0K | $903.0K | $710.0K | ||
| Depreciation & Amortization | -- | $-442.0K | $834.0K | $690.0K | $816.0K | $896.0K | $903.0K | $710.0K | ||
| Amortization | -- | -- | -- | -- | $342.0K | $774.0K | $855.0K | $855.0K | ||
| Other Operating Expenses | $-32.4M | $-78.4M | $629.0K | $551.0K | $551.0K | $551.0K | $551.0K | -- | ||
| OPERATING INCOME | ||||||||||
| Operating income | $-32.4M | $-78.4M | $-146.0M | $-136.6M | $-170.1M | $-179.2M | $-184.4M | $-265.5M | ||
| EBITDA | $-33.5M | $-73.6M | $-139.9M | $-133.3M | $-68.5M | $-171.2M | $-192.2M | $-266.9M | ||
| NON-OPERATING ITEMS | ||||||||||
| Interest Expense (Non-Operating) | -- | -- | -- | -- | -- | $5.2M | $13.9M | -- | ||
| Intinc | $-1.3M | $4.4M | $5.3M | $2.6M | $447.0K | -- | -- | -- | ||
| Net Non-Operating Interest Income/Expense | $-1.3M | $4.4M | $5.3M | $2.6M | $447.0K | $1.2M | $-53.0K | -- | ||
| Gain on Sale of Securities | -- | -- | -- | -- | $447.0K | $4.0M | $13.9M | $23.6M | ||
| Other Income/Expense | -- | -- | $-5.3M | -- | $-100.4M | $-790.0K | $-14.1M | $-25.9M | ||
| Other Special Charges | -- | -- | $5.3M | -- | $100.0M | $-790.0K | $190.0K | $2.2M | ||
| PRE-TAX INCOME | ||||||||||
| EBIT | $-33.7M | $-74.1M | $-140.7M | $-134.0M | $-69.6M | $-175.9M | $-184.1M | $-260.3M | ||
| Pre-Tax Income | $-33.7M | $-74.1M | $-140.7M | $-134.0M | $-69.6M | $-181.1M | $-184.1M | $-260.3M | ||
| INCOME TAX | ||||||||||
| Tax Provision | -- | -- | -- | -- | -- | -- | $564.0K | $346.0K | ||
| NET INCOME | ||||||||||
| Net Income | $-33.7M | $-148.1M | $-140.7M | $-134.0M | $-69.6M | $-181.1M | $-184.7M | $-260.6M | ||
| Net Income (Continuing Operations) | $-33.7M | $-148.1M | $-140.7M | $-134.0M | $-69.6M | $-181.1M | $-184.7M | $-260.6M | ||
| Net Income (Discontinued Operations) | $-33.7M | $-148.1M | $-140.7M | $-134.0M | $-69.6M | $-181.1M | $-184.7M | $-260.6M | ||
| Net Income (Common Stockholders) | $-33.7M | $-148.1M | $-140.7M | $-134.0M | $-69.6M | $-181.1M | $-184.7M | $-264.6M | ||
| Normalized Income | -- | -- | -- | -- | -- | -- | -- | $-234.5M | ||
| TOTALS | ||||||||||
| Total Expenses | $32.4M | $-78.4M | $146.0M | $136.6M | $173.2M | $202.8M | $261.8M | $395.6M | ||
| SHARE & EPS DATA | ||||||||||
| Average Shares Outstanding | $13.3M | $31.0M | $36.4M | $44.1M | $49.6M | $52.1M | $57.7M | $61.0M | ||
| Average Shares Outstanding (Diluted) | $11.9M | $62.0M | $36.4M | $44.1M | $49.6M | $52.1M | $57.7M | $61.0M | ||
| Shares Outstanding | $27.3M | $34.4M | $44.1M | $50.2M | $50.3M | $56.7M | $60.1M | $63.2M | ||
| Basic EPS | -- | -- | $-3.86 | $-3.04 | $-1.4 | $-3.47 | $-3.2 | $-4.34 | ||
| Basic EPS (Continuing Operations) | -- | -- | $-3.86 | $-3.04 | $-1.4 | $-3.47 | $-3.2 | $-4.34 | ||
| Diluted EPS | $-2.83 | $-2.39 | $-3.86 | $-3.04 | $-1.4 | $-3.47 | $-3.2 | $-4.34 | ||
| Diluted EPS (Continuing Operations) | -- | -- | -- | -- | $-1.4 | $-3.47 | $-3.2 | $-4.34 | ||
| OTHER METRICS | ||||||||||
| Accrued Preferred Stock Dividends | -- | -- | -- | -- | -- | -- | -- | $-4.0M | ||
| Acquisition Expense | -- | -- | -- | -- | -- | $62.0K | -- | -- | ||
| Net Income Extraordinary | -- | $-74.1M | $-140.7M | -- | -- | -- | -- | -- | ||
| Other Gand A | $-215.0K | $-359.0K | $36.5M | $46.1M | $68.5M | $92.0M | $117.5M | $144.3M | ||
| Other Write Off | -- | -- | -- | -- | $95.0K | $1.3M | $12.2M | $23.2M | ||
| Otherunder Preferred Stock Dividend | -- | -- | -- | -- | -- | -- | -- | $-4.0M | ||
| Preferred Stock Dividends | -- | -- | -- | -- | -- | -- | -- | $-4.0M | ||
| Rent And Landing Fees | $-215.0K | $-359.0K | -- | -- | -- | -- | -- | -- | ||
| Selling Expense | $9.5M | $28.1M | -- | -- | -- | -- | -- | -- | ||
Financial data is updated quarterly and may not reflect the most recent earnings.
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | RYTM | $99.00 | +3.1% | 771.63K |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |
Get Rhythm Pharmaceuticals Inc. Data in Excel
Stream real-time data directly to your spreadsheets
BUY NOW